Santoni, N. (2017) “Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil”, Jornal Brasileiro de Economia da Saúde, 9(1), p. 73–82. doi: 10.21115/JBES.v9.n1.p73-82.